Patrick Thiaville is chief scientific officer of Exothera Nucleic Acids, a viral vector CDMO (contract manufacturing and development organization) using standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines...
Hayley Crowe is executive vice president and general manager of Ecolab’s Global Life Sciences sector, comprised of Ecolab’s Purolite and pharma / personal care businesses. We sat down with Hayley to discuss how adversity inspired her determination to...
Following positive advice from the Scottish Medicines Consortium (SMC), the first biologic treatment for inflammatory skin disease, hidradenitis suppurativa (HS), is now available in Scotland on the NHS.
Rani Therapeutics, a clinical-stage biotherapeutics company focused on the oral delivery of biologics, has announced encouraging results from its phase 1 study of RT-111, a RaniPill capsule containing an ustekinumab biosimilar, CT-P43.
Ion exchange resin manufacturer Purolite and bioprocessing technology firm Repligen have announced the commercial launch of Praesto CH1, an affinity resin designed to purify specialized mAbs such as bispecifics and recombinant antibody fragments.
Biotherapeutics company MediWound has secured an additional $6.7 million in funding from the US Department of Defense to advance its non-surgical burn treatment for the US Army.
As it extends its cash runway, the cell therapy developer Atara Biotherapeutics has expanded a partnership with Pierre Fabre Laboratories to commercialize the off-the-shelf T-cell therapy tabelecleucel (tab-cel) for a rare form of blood cancer.
Polpharma Biologics, an international biotech company developing and manufacturing biosimilars, has announced that the European Commission (EC) has approved Tyruko (natalizumab) as the first and only biosimilar for relapsing forms of multiple sclerosis...
Bora Pharmaceuticals, an international contract development and manufacturing organization (CDMO), has announced the opening of a new state-of-the-art facility in Taoyuan City, Taiwan.
Teva Pharmaceuticals, a provider of generic and innovative medicines, and Alvotech, a biotech company specializing in the development and manufacture of biosimilar medicines, have expanded their existing partnership agreement.
Biotechs located in the US received 19% or $7.6 billion more venture financing from 2018-2023 (YTD) for biologic innovator drugs compared to small molecule counterparts, driven by inflation law to drive down prescription drug prices, reveals GlobalData....
Samsung Biologics’ upcoming fifth plant will be operational by April 2025, five months earlier than previously expected, the biotech company revealed at BIO International Convention on Monday 5.
Bora Pharmaceuticals is a pharmaceutical company that provides solutions for the development, manufacturing, and packaging of pharmaceutical products. In the large molecule space, it offers comprehensive services from the development of mammalian cell...
Genentech is to build a new biologics facility at its Oceanside, California campus that it says will be at the forefront of next-generation manufacturing and environmentally sustainable production for small-batch commercial biologics.
Despite an uncertain macroeconomic environment, Lonza says its ‘resilient’ business model and sustained market demand delivered a strong financial performance in 2022, in line with the Swizterland based CDMO’s outlook.
Celltrion, one of Korea’s largest biopharma companies, will be Rani’s exclusive supplier of ustekinumab biosimilar, CT-P43, for its oral RT-111 RaniPill program.
Global pharma giants, GSK, Sanofi, and Takeda, are set to collaborate with Singapore-based researchers to boost innovation in local biologics and vaccines manufacturing.
The biopharma sector has seen recent advancements in process intensification, especially in relation to upstream processing, with the technology employed aimed at increasing drug output. One of the quickest and simplest ways to achieve process intensification...
A ‘significant shift’ is under way in global outsourcing strategies: with the sector moving away from phase-appropriate development in favor of a more forward-looking model – with experts advising starting the search for an outsourcing partner as early...
South Korean multinational, Lotte Corporation, is to acquire Bristol Myers Squibb's manufacturing facility in East Syracuse, New York. The deal is reportedly worth US$160m.
The US will play a key role in the development of advanced manufacturing technologies, predicts a report commissioned by CPhI North America ahead of the 2022 show.
Catalent has announced a multi-year $350m investment at its facility in Bloomington, Indiana, to expand biologics drug substance and drug product manufacturing capabilities.
Bionova Scientific, a US biologics CDMO, is to be acquired by the US arm of Asahi Kasei Medical, part of the Asahi Kasei Group, owned by Tokyo based Asahi Kasei Corporation.
Catalent completes expansion of its biologics manufacturing network by upgrading its Limoges, France, location with additional capacity and the ability to produce large molecules.
The US Health and Human Services (HHS) Office of Inspector General (OIG) is to launch a study on the use and spending trends for biosimilars in Medicare Part B.
Contract development and manufacturing organization (CDMO), Recipharm, is now better placed to serve the advanced therapy medicinal products (ATMPs) market through two deals announced today.
The biologics CDMO market is expected to grow by US$8.65bn from 2021 to 2026, at a CAGR of 12.2% during the forecast period, according to new market data from Technavio.
Contract development and manufacturing organization (CDMO), Recipharm, has acquired GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material.
Protagen, BioAnalytix, and GeneWerk this week announced their unified operations and re-brand as ProtaGene, a CRO partner for the biologics and cell and gene therapy developers, from discovery to commercialization.
Waters Corporation and Sartorius are partnering with the aim of providing bioprocess experts with direct access to high-quality mass spectrometry (MS) data to accelerate the speed and improve the accuracy of biopharmaceutical process development.
The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims a new report from Roots Analysis.
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
Absci Corp, a synthetic biology firm, is partnering with pharma company, EQRx, to jointly engineer and develop several clinical candidates across multiple therapeutic areas, including oncology and immunology.
The operation of the 1.5 million square-foot biologics manufacturing site in Lengnau, Switzerland is part of a strategic partnership agreed with CSL Limited, announced last year, says Thermo Fisher Scientific.
3i Group plc has partnered with a former Lonza executive to create a ‘pure-play, patient-centric and sustainable’ biologics drug product contract development and manufacturing organization (CDMO).
Ardena has acquired Idifarma, a contract manufacturer of niche and highly potent generic and innovative drugs, from Suanfarma; the deal enables it to expand across Southern Europe and supports its strategy to become a leading global CDMO.
